ACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy

J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):633-41. doi: 10.1177/1470320313515036. Epub 2014 Jan 22.

Abstract

Introduction: Little is known about genetic predictors that modify the renoprotective effect of renin-angiotensin system (RAS) blockade in IgA nephropathy (IgAN).

Materials and methods: The present multicenter retrospective observational study examined effect modification between RAS blockade and three RAS-related gene polymorphisms in 237 IgAN patients, including ACE I/D (rs1799752), AT1R A1166C (rs5186) and AGT T704C (rs699).

Results: During 9.9 ± 4.2 years of observation, 63 patients progressed to a 50% increase in serum creatinine level. Only ACE I/D predicted the outcome (ACE DD vs ID/II, hazard ratio 1.86 (95% confidence interval 1.03, 3.33)) and modified the renoprotective effect of RAS blockade (p for interaction between ACE DD and RAS blockade = 0.087). RAS blockade suppressed progression in ACE DD patients but not in ID/II patients (ACE ID/II with RAS blockade as a reference; ID/II without RAS blockade 1.45 (0.72, 2.92); DD without RAS blockade 3.06 (1.39, 6.73); DD with RAS blockade 1.51 (0.54, 4.19)), which was ascertained in a model with the outcome of slope of estimated glomerular filtration rate (p = 0.045 for interaction).

Conclusion: ACE I/D predicted the IgAN progression and the renoprotective effect of RAS blockade in IgAN patients whereas neither AT1R A1166C nor AGT T704C did.

Keywords: ACE I/D; AGT T704C; AT1R A1166C; Candidate gene approach; PREDICT-IgAN; interaction; renal prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biopsy
  • Blood Pressure / drug effects
  • Creatinine / blood
  • Female
  • Glomerulonephritis, IGA / drug therapy*
  • Glomerulonephritis, IGA / enzymology
  • Glomerulonephritis, IGA / genetics*
  • Glomerulonephritis, IGA / physiopathology
  • Humans
  • INDEL Mutation / genetics*
  • Kidney / drug effects
  • Kidney / pathology
  • Male
  • Polymorphism, Single Nucleotide / genetics*
  • Protective Agents / pharmacology
  • Protective Agents / therapeutic use
  • Renin-Angiotensin System* / drug effects

Substances

  • Protective Agents
  • Creatinine